Results for tag: "Hepatocellular Carcinoma Drug"

The Hepatocellular Carcinoma Drug market is a subset of the Oncology Drugs market. It is composed of drugs used to treat hepatocellular carcinoma (HCC), a type of liver cancer. These drugs are used to reduce the size of tumors, slow the growth of cancer cells, and reduce symptoms. Commonly used drugs include sorafenib, lenvatinib, and regorafenib. Other treatments, such as chemotherapy, radiation therapy, and surgery, may also be used in combination with these drugs. The Hepatocellular Carcinoma Drug market is highly competitive, with many companies offering treatments for HCC. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. Other companies, such as AbbVie, AstraZeneca, and Eli Lilly, also offer treatments for HCC. Show Less Read more